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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Placebo and Other Interventions in Asthma
To the Editor: Wechsler et al. (July 14 issue)1 
describe self-reported outcomes of albuterol treat-
ment as compared with placebo in patients with 
mild-to-moderate asthma. One possible expla-
nation for the lack of incremental benefit with 
respect to these outcomes may be related to the 
experimental design of the study. The benefit of 
the bronchodilator effect of albuterol could have 
not been appreciated by patients who were prob-
ably asymptomatic and had baseline mild airway 
obstruction, particularly because they were eval-
uated under resting conditions for 2 hours in a 
hospital setting. More information could have 
been obtained about subjective outcomes by allow-
ing the patients to do some standardized tasks 
that simulate real-life conditions such as walking 
or climbing stairs and not just remaining seated 
in a hospital waiting room.
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To the Editor: Wechsler et al. underline the rel-
evance of the placebo effect in patients with asth-
ma, and they compare placebo with no treatment. 
Despite the strengths of the study design, we com-
pletely disagree with their conclusions, in which 
they extrapolate that “patient self-reports can be 
unreliable” and so “objective outcomes should be 
more heavily relied on for optimal asthma care.” 
These statements are not acceptable as a deduction 
because the authors did not study clinical out-
comes other than patients’ symptoms at one time.
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To the Editor: Regarding Moerman’s editorial1 
concerning the study of interventions for asthma 
reported on by Wechsler et al.: first, Moerman 
categorizes inflammatory bowel disease as a “sub-
jective and functional condition” like migraine 
or back pain. The concept of inflammatory bow-
el disease being a functional disorder has been 
abandoned.2 Second, he concludes, “a patient-cen-
tered approach requires that patient-preferred out-
comes trump the judgment of the physician.” This 
statement is problematic because the decision to 
rely on patient-centered items, physician-deter-
mined biologic markers, or a combination of the 
two for measurement of outcomes in a given dis-
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ease should be guided, in part, by the appraisal 
of whether the persistence of untreated biologic 
abnormalities will result in organ damage or not. 
The stronger the effect of the altered biologic 
markers on the disease course, the more critical 
their assessment becomes. For example, arterial 
hypertension may be asymptomatic, but failing to 
treat it can have serious consequences. As such, 
the efficacy of therapeutic interventions should be 
judged on the basis of a continuum of patient-
oriented outcomes and biologic measures, the bal-
ance between which is highly disease-specific.3,4
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The Authors Reply: Rolla and Bucca postulate 
that our finding of a lack of incremental benefit 
of albuterol over placebo for subjective outcomes 
in patients with asthma was due in part to the fact 
that these persons were tested at rest. Although 
it is possible that the degree of physiological def-
icit in some of these patients may not have been 
clinically significant enough for them all to have 
symptoms at rest, not all patients with asthma 
who have deficits in lung function appreciate the 
degree to which their asthma contributes to symp-
toms of airf low limitation until they are given 
bronchodilators, with resultant improvement in 
lung function and symptoms.1-4 
In our study, active bronchodilator resulted in 
a substantial improvement in lung function as 
compared with no treatment control (20.1% vs. 
7.1% improvement in the forced expiratory vol-
ume in 1 second), and patients were able to per-
ceive this difference (50% vs. 21% improvement 
in symptoms). The fact that these patients reported 
improvements and that these improvements dif-
fered among patients who received no treatment 
and the other treatments suggests that these pa-
tients had a degree of symptoms at rest; otherwise, 
they could not have detected improvement, and a 
differential improvement, at that. Had we tested 
the subjects under stress, we suspect that the dif-
ferences we observed would have been magnified, 
since there would have been even more room for 
improvement. 
Although we value and recognize the impor-
tance of patient self-reports in the treatment of the 
individual patient, we disagree with the comments 
by Bibalo et al. and maintain that patient self-
reports can be unreliable and that patients have 
a considerable response to placebo. This finding 
has been observed by us and by many others5 and 
is the reason we believe that subjective outcomes 
need to be put in the context of concurrent ob-
jective findings in the management of asthma.
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The Editorialist Replies: Straumann et al. make 
several assertions. Many bowel disorders have vary-
ing physical signs, but many of them cause only 
symptoms that are often extremely debilitating. 
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None of them seem to be curable, but most symp-
toms fluctuate over time, and some may be man-
ageable with treatments that are associated with 
varying amounts of distress. Clearly, regular and 
supportive doctor−patient discussions about what 
is possible in such conditions, as well as what is 
desirable, are probably in order in most of these 
illnesses.
Hypertension, of course, is entirely different 
in that it causes no symptoms at all and can be 
diagnosed only by screening followed by treat-
ments, many of which have side effects that 
limit their clinical usefulness. Hence, reliable 
treatment is problematic (as attested by 6508 cita-
tions identified with the PubMed query “hyper-
tension compliance”) but preferable to prevent 
complication. The solution to this dilemma is, 
again, conversations between the patient and 
caregiver.
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Vemurafenib in Melanoma with BRAF V600E Mutation
To the Editor: In the study by Chapman et al. 
(June 30 issue),1 vemurafenib clearly improved rates 
of overall and progression-free survival among 
patients with untreated melanoma with the BRAF 
V600E mutation. Since half of cutaneous mela-
nomas carry this activating mutation, the admin-
istration of vemurafenib to patients with muta-
tion-bearing melanomas has the potential to 
change the grim prognosis associated with this 
disease. We have two questions. First, was there 
any correlation between drug response and the 
ratio of mutant to wild-type alleles (BRAF ampli-
fication)? Second, we wonder whether any intrin-
sic or acquired resistance to vemurafenib, or both, 
could result from the existence or emergence of 
drug-resistant mutations in the genes related to 
the alternative mitogen-activated protein kinase 
(MAPK) signaling pathway.2 Such secondary mu-
tations might explain the high frequency of cuta-
neous squamous-cell carcinoma and keratoacan-
thoma observed in the vemurafenib group.
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To the Editor: Vemurafenib is an inhibitor of 
mutated BRAF. The phase 3 trial of this agent for 
the treatment of metastatic melanoma showed 
impressive results.1
In our center, five patients with metastatic 
melanoma with the V600E mutation who received 
vemurafenib and six patients who received dacar-
bazine underwent systematic total body-surface 
monitoring of skin with a dermoscope. Six atypi-
cal lesions were removed in four patients in the 
vemurafenib group; these patients were otherwise 
having a response to treatment between week 4 
and week 12. The lesions were small. Two local 
dermatopathologists and one additional expert 
diagnosed five early primary melanomas (such as 
the one shown in Fig. 1) and one dysplastic ne-
vus. All of the lesions were wild-type for BRAF.
The effect of V600E BRAF inhibitors on BRAF 
wild-type melanocytic lesions is a crucial unre-
solved question.2 Paradoxical activation of the 
RAF-MEK-ERK pathway by CRAF activation has 
been suggested by in vitro studies.3 Unlike vemu-
rafenib-induced squamous-cell carcinomas, early 
changes in melanocytic lesions are difficult to 
identify and require examination with the use of 
dermoscopy.
Observation of early BRAF wild-type primary 
melanomas in vemurafenib-treated patients, who 
otherwise had a clinically significant response, 
suggests a different behavior of melanoma cells 
according to their BRAF status and highlights the 
importance of repeated skin examination, includ-
ing dermoscopy, in these patients.4
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